Citius Pharmaceuticals initiated with a Buy at EF Hutton

EF Hutton analyst Jason Kolbert initiated coverage of Citius Pharmaceuticals with a Buy rating and $6 price target. Citius has two late-stage therapeutics, Mino-Lok and LYMPHIR, which both have demonstrated efficacy and safety and are in the final stages of the approval process, the analyst tells investors in a research note. A planned IPO for Citius Pharma’s wholly owned oncology subsidiary this summer, coupled with an early August PDUFA date, should be catalysts to unlock value for the parent, the analyst added.